AAIPharma CEO Discusses Parenteral Manufacturing - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

AAIPharma CEO Discusses Parenteral Manufacturing
AAIPharma Services CEO Patrick Walsh talks about the parenterals market and the drivers for his company's recent expansion of its sterile-manufacturing capabilities.


Pharmaceutical Sciences, Manufacturing & Marketplace Report

There is growing demand for parenterals manufacturing, but currently limited production capacity, particularly for pharmaceutical companies looking for a range of capabilities from development through commercial scale.

To help address that need, AAIPharma Services recently expanded its sterile-manufacturing operations. AAIPharma Services CEO Patrick Walsh spoke with the Pharmaceutical Sciences, Manufacturing, and Marketplace Report about the parenterals market and the additional capabilities his company felt were important to include, such as line-loss techniques.

What drivers led AAIPharma to expand its parenteral manufacturing? Walsh points to a shortage of qualified manufacturing facilities in the US and internationally, a shortage of key raw material components, and other issues. Hear more of what he has to say (Part Ⅰ).

What specific capabilities and equipment did AAIPharma incorporate into its new facility and why? Why was it important for the expanded facility to specifically address line-loss issues and what techniques were selected? Listen to what Walsh has to say (Part Ⅱ).

For Walsh, ensuring that the needs of AAIPharma’s customers continued to be met during the physical upgrading of its parental manufacturing operations was one of the biggest challenges the company faced when planning the expansion. Hear how the company overcame that hurdle (Part Ⅲ).

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
11%
Provide treatment for patients globally.
9%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
Source: Pharmaceutical Sciences, Manufacturing & Marketplace Report,
Click here